Merck will share proprietary data with Isomorphic Labs, whose IsoDDE engine will design small-molecule drug candidates for a single oncology target.
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.
What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable.
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Roche picks the targets and Hansoh builds the ADCs under a deal with $400 million upfront, a $110 million first-anniversary payment and more than $15 billion in milestones. The split mirrors AstraZeneca’s January deal with CSPC.
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
The magic mushroom compound psilocybin, which has had favorable results in two Phase 3 trials of depression and could be available as soon as 2027, has shown promise in rodents as a potential preventative for Chemotherapy‑Induced Peripheral Neuropathy (CIPN), a disabling pain condition caused by chemotherapy that affects about 30% to 50% of patients receiving chemotherapy. A 2014 review found that 68.1% of chemotherapy patients across 31 studies had CIPN when measured in…
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapies for cancer, autoimmune diseases and chronic inflammatory and metabolic disorders, in partnership with Case Western Reserve University and University Hospitals Cleveland Medical Center, published preclinical results for a…
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The companies are investigating the vaccine as a combination treatment with Merck’s Keytruda, a monoclonal antibody that targets the PD-1 receptor on T-cells, breaking a pathway…
As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form
As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit. …
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ, a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in…
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, Moderna signalled a strategic expansion beyond its established vaccine and rare disease franchises, unveiling new programs in in vivo CAR-T and solid tumor oncology. The firm also revealed an AI-driven research platform it says will accelerate the pace of drug discovery across its pipeline. The company publicly revealed two…
Calderasib’s real innovation: designed for combinability and potency
Merck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. The KRAS gene encodes a protein that signals for cell growth. It cycles between active and inactive states, signaling when cells should divide. Although it is one of the most commonly…
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
Biotech is heating up again. The SPDR S&P Biotech ETF (XBI) has gained roughly 69% over the past year. Global life sciences M&A hit $240 billion in 2025, an 81% jump from the prior year, with EY reporting a record $2.1 trillion in deal capacity. Goldman Sachs expects broader M&A volume to rise sharply in…
BioNTech made €19B in 2021. This quarter: €118M. Now it’s cutting 1,860 jobs and betting €16.8B in cash on returning to its oncology roots.
The German mRNA specialist BioNTech made a fortune through its alliance with Pfizer. BioNTech launched “Project Lightspeed” in January 2020, days after the SARS-CoV-2 genetic sequence went public. It received €375M from the German government to accelerate development and production. Pfizer declined U.S. government support in the form of Operation Warp Speed R&D funding to…
UCLA researchers advance EGFR-targeted drug for glioblastoma into clinical testing
Researchers at UCLA are advancing a glioblastoma drug candidate designed specifically for the biology and anatomy of brain tumors. Early clinical testing showing signs that the therapy can reach the brain at potentially meaningful levels. The drug, KTM-101, was developed to target alterations in epidermal growth factor receptor, or EGFR, a molecular driver found in…
Small study suggests probiotic yogurt strain may boost immunotherapy response in lung cancer
Immunotherapy has transformed lung cancer treatment, significantly improving patients’ treatment prospects. But gaps remain. In non-small cell lung cancer, 27 to 46% of patients respond to initial checkpoint inhibitor therapy, and of those who do, the majority develop resistance within four years, according to a study in Cancers 2024. What if a natural polymer produced…
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
Researchers in China have used pig semen to develop eye drops that can deliver cancer drugs to the back of the eye. In a mouse model of retinoblastoma, the drops killed cancer cells and slowed tumor growth, the scientists reported in Science Advances. Most therapies that need to reach the retina use injections that can…
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Merck is an A+ credit, a global oncology powerhouse, and still, about half its 2024 pharma revenue came from a single product: Keytruda, a product whose loss of exclusivity will hit around 2028 in the U.S. S&P Global Ratings calls that kind of concentration a “material weakness.” Merck isn’t alone. A new S&P analysis of…
Developments in breast cancer: What’s new from SABCS 2025
SABCS 2025 showcased several new strides in breast cancer research, which continues to be one of the most diagnosed malignancies globally, owing to the breadth of its subtypes: HR+, HER2+ and TNBC, all of which respond differently. In recent years, there have been several leaps in treatment options that have improved both outcomes and overall…
Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer
You said:Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer Giredestrant, an experimental oral selective estrogen receptor degrader, reduced the risk of invasive disease recurrence or death by 30% compared with standard hormone therapy in a phase 3 trial of more than 4,100 patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.…
HPV vaccine shrinks cervical tumors in mice
A nasal HPV vaccine has been shown to shrink cervical cancer tumors in mice, researchers reported in Science Translational Medicine last month. The vaccine targets HPV16 E7, a protein made by the human papillomavirus (HPV) that targets a tumor suppressor and causes uncontrolled cell growth. Unlike most vaccines, which are preventative, this medicine could be…
How bioprospecting revealed a scorpion venom that kills breast cancer cells
Researchers at the University of São Paulo’s Ribeirão Preto School of Pharmaceutical Sciences (FCFRP-USP) in Brazil have found a molecule in the venom of Brotheas amazonicus, a species of scorpion native to the Amazon, which appears to attack breast cancer cells in a way similar to a widely used chemotherapy medication. Their findings were presented…
First FDA-approved treatment for lymphoma (CTCL) in seven years
On Monday, Citius Oncology announced the U.S. launch of Lymphir (denileukin diftitox-cxdl), the first FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) since 2018. Lymphir is an IL-2 receptor-directed fusion protein that kills cancer cells by binding to the IL-2 receptors found on the regulatory T-cells and releasing a toxin that inhibits protein…
Precision medicine made trials smarter. It also made recruitment harder.
In statistics and machine learning, there’s a tradeoff between precision and recall: tune a system to be more selective and you inevitably miss more true positives. Cancer clinical trials have stumbled into a similar trap. As oncology has shifted from tumor-type-centered studies to gene-directed approaches, eligibility criteria have grown exquisitely precise. Instead of enrolling patients…
FDA gives double approval of lung cancer diagnostic and treatment
The FDA has granted simultaneous approval for HERNEXEOS (zongertinib tablets), developed and commercialized by Boehringer Ingelheim, for the treatment of adult patients with non-small cell lung cancer (NSCLC). The approval covers tumors with HER2 (ERBB2) activating mutations. It also signed off on Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to…
AstraZeneca and U.S. government made a deal to lower drug prices for Americans
AstraZeneca announced a deal with the U.S. government to lower drug prices for American patients last Friday. According to the press release, AstraZeneca agreed “to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.” Under the agreement, AstraZeneca will provide Direct-to-Consumer (DTC)…
























